5 completed, 1 unknown. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow DBV Technologies: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children DBV1605 - Cow's Milk Allergy | Phase 2 | Unknown | DBV Technologies | 230 | 2020-08-28 | 2022-08-11 |
| Milk Patch for Eosinophilic Esophagitis Viaskin Milk 500 mcg, Viaskin Placebo - Eosinophilic Esophagitis, Milk Allergy | Phase 2 | Completed | Children's Hospital of Philadelphia | 20 | 2015-10-01 | 2019-07-10 |
| Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy Viaskin Milk 150 mcg, Viaskin Milk 300 mcg, Viaskin Milk 500 mcg - Food Allergy | Phase 1 / Phase 2 | Completed | DBV Technologies | 198 | 2014-11-01 | 2024-11-20 |
| Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children Viaskin Peanut 250 mcg - Peanut Allergy | Phase 2 | Completed | DBV Technologies | 171 | 2013-09-01 | 2022-06-30 |
| Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg - Peanut Allergy | Phase 2 | Completed | DBV Technologies | 221 | 2012-08-01 | 2021-10-27 |
| Epicutaneous Immunotherapy in Peanut Allergy in Children Epicutaneous Immunotherapy, placebo of peanut - Peanut Allergy | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 60 | 2010-08-01 | 2026-08-21 |
Food Hypersensitivity (4) · Milk Hypersensitivity (3) · Peanut Hypersensitivity (3) · Hypersensitivity, Immediate (2) · Eosinophilic Esophagitis (1)
United States (5) · Canada (4) · France (3) · Netherlands (2) · Italy (1) · Lithuania (1) · Poland (1)
Antonella Cianferoni, MD, PhD (1) · Christophe Dupont, MD, PhD (1)